SecBot SecBot
8-K ·Filed Aug 4, 2026

RIGL

RIGEL PHARMACEUTICALS INC
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001034842-26-000053
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Watch for initial VEPPANU sales in Q3 2026 as the first commercial PROTAC; R289 Phase 1b data by year-end could be a catalyst. The raised revenue guidance implies confidence in core product growth, but cash burn from the $70M upfront payment merits monitoring for potential capital needs.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$40.48
T+0 close · Aug 4, 2026 · via day close
Latest settled
+25.79%
T+60 · $50.92
Vs SPY
+25.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $40.48entry
  2. T+1 · 3mo ago −3.11%α −2.95% · $39.22
  3. T+5 · 3mo ago +3.43%α +3.08% · $41.87
  4. T+20 · 3mo ago +22.09%α +22.69% · $49.42
  5. T+60 · 19d ago +25.79%α +25.60% · $50.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rigel Pharmaceuticals reported Q2 2026 revenue of $78.7M (net product sales $67.0M, +14% YoY) and EPS of $0.88, missing consensus of $0.91 by 3.3%. The company raised full-year 2026 revenue guidance to $285-295M (from $275-290M), reflecting strong core product sales momentum. The in-license of VEPPANU (vepdegestrant), the first FDA-approved PROTAC for ER+/HER2- breast cancer, expands the commercial portfolio, but the $70M upfront payment drew down cash to $95.3M from $155M at year-end 2025.

Key Financial Metrics

EPS
$0.88
est $0.91 · -3.3%
Revenue
$78.7M
-22.6% YoY
Rating
miss
Guidance
$285M-$295M
raised
Gross Margin
87.3%

Key Facts

  • Q2 2026 total revenues of $78.7M (net product sales $67.0M + contract revenue $11.7M)
  • Product sales grew 14% YoY; TAVALISSE +18%, REZLIDHIA +27%; GAVRETO -10%
  • GAAP diluted EPS $0.88 (consensus $0.91), 3.3% miss
  • Raised 2026 revenue guidance to $285-295M from prior $275-290M
  • In-licensed VEPPANU (vepdegestrant) from Arvinas/Pfizer; U.S. launch expected mid-August
  • Cash and investments $95.3M vs $155.0M at Dec 2025, after $70M upfront payment for VEPPANU
  • R289 Phase 1b in lower-risk MDS on track for dose selection and preliminary data by year-end 2026
  • Net income of $17.3M vs $59.6M in Q2 2025 (prior year included $40M non-cash Lilly revenue release)

Financial Impact

EPS miss of ~$0.03 vs consensus (-3.3%) but raised revenue guidance by ~$7.5M at midpoint; VEPPANU launch could add incremental revenue in H2 2026

epsrevenuecashguidance

Risk Factors

  • VEPPANU commercial launch uncertainty and competition in ER+/HER2- metastatic breast cancer
  • GAVRETO net product sales declining 10% YoY
  • Cash drawdown to $95.3M may require future financing if operating cash flow turns negative
  • Phase 1b R289 data may not meet expectations
  • Dependence on TAVALISSE for ~60% of product sales

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001034842-26-000053
Document: 0001034842-26-000053-index.html0001034842-26-000053
Document: 0001034842-26-000053.txt0001034842-26-000053
8-K Data (Synthetic)0001034842-26-000053

Track record

12 reports on RIGL

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.02% at T+60 after the May 12, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $44.21 Now $43.73 −1.09% settles Feb 12
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
  4. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $39.65 Now $43.73 −10.29% settles Feb 4
  5. Aug 4, 202614w ago 8-K Mixed 6/10 Viewing Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
  6. Jun 17, 202621w ago 8-K Neutral 4/10 Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
  8. May 20, 202625w ago 8-K Neutral 2/10 Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
  9. May 12, 202626w ago 8-K Bullish 7/10 Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
  10. May 5, 202627w ago 8-K Bearish 7/10 Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026